Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033371 · ClinicalTrials.gov registry record · Phase 2
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
NCT00033371: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00033371 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 205 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00033371, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well giving celecoxib with or without eflornithine works in preventing colorectal cancer in patients with familial adenomatous polyposis. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of celecoxib and eflornithine may keep cancer from forming in patients with familial adenomatous polyposis.
Interventions
- OTHER Placebo
- DRUG Celecoxib
- OTHER Questionnaire administration
- OTHER Laboratory biomarker analysis
- DRUG eflornithine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2001-12-13 |
| Est. Completion | 2009-03-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00033371
The ClinicalTrials.gov registry entry for NCT00033371 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00033371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00033371 about?
NCT00033371 is a clinical study titled "Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis". This randomized phase II trial studies how well giving celecoxib with or without eflornithine works in preventing colorectal cancer in patients with familial adenomatous polyposis. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of celecoxib and eflornithine may keep...
What is the current status of trial NCT00033371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2001-12-13. Estimated completion is 2009-03-24.
What interventions are being tested in trial NCT00033371?
The interventions under investigation include: Placebo (OTHER), Celecoxib (DRUG), Questionnaire administration (OTHER), Laboratory biomarker analysis (OTHER), eflornithine (DRUG).
Who is sponsoring clinical trial NCT00033371?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.